MMSET is the key molecular target in t(4;14) myeloma

por Mirabella, F, Wu, P, Wardell, C P, Kaiser, M F, Walker, B A, Johnson, D C, Morgan, G J
Publicado 2013

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

por Walker, B A, Wardell, C P, Brioli, A, Boyle, E, Kaiser, M F, Begum, D B, Dahir, N B, Johnson, D C, Ross, F M, Davies, F E, Morgan, G J
Publicado 2014

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

por Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C.
Publicado 2021

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

por Pawlyn, C, Bright, M D, Buros, A F, Stein, C K, Walters, Z, Aronson, L I, Mirabella, F, Jones, J R, Kaiser, M F, Walker, B A, Jackson, G H, Clarke, P A, Bergsagel, P L, Workman, P, Chesi, M, Morgan, G J, Davies, F E
Publicado 2017

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

por Shah, V, Sherborne, A L, Walker, B A, Johnson, D C, Boyle, E M, Ellis, S, Begum, D B, Proszek, P Z, Jones, J R, Pawlyn, C, Savola, S, Jenner, M W, Drayson, M T, Owen, R G, Houlston, R S, Cairns, D A, Gregory, W M, Cook, G, Davies, F E, Jackson, G H, Morgan, G J, Kaiser, M F
Publicado 2018

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach

por Went, M, Sud, A, Law, P J, Johnson, D C, Weinhold, N, Försti, A, van Duin, M, Mitchell, J S, Chen, B, Kuiper, R, Stephens, O W, Bertsch, U, Campo, C, Einsele, H, Gregory, W M, Henrion, M, Hillengass, J, Hoffmann, P, Jackson, G H, Lenive, O, Nickel, J, Nöthen, M M, da Silva Filho, M I, Thomsen, H, Walker, B A, Broyl, A, Davies, F E, Langer, C, Hansson, M, Kaiser, M, Sonneveld, P, Goldschmidt, H, Hemminki, K, Nilsson, B, Morgan, G J, Houlston, R S
Publicado 2017